Search results for "adjuvants"

showing 10 items of 151 documents

Quality and antioxidant response of gilthead seabream (Sparus aurata L.) to dietary supplements of fenugreek (Trigonella foenum graecum) alone or com…

2017

The present study was conducted to determine the potential effect of the dietary intake of fenugreek (Trigonella foenum graecum) seeds alone or in combination with Bacillus licheniformis, Lactobacillus plantarum or B. subtilis on gilthead seabream quality and antioxidant response after 2 and 3 weeks of experimental feeding. The results showed that the supplements did not affect the percentage of the fatty acid profiles of muscle, demonstrating that all the additives tested can be administrated without any negative effect on biochemical composition and quality of gilthead seabream. The quantification of thiobarbituric acid reactive substances in muscle demonstrated the significant beneficial…

0301 basic medicineTrigonellaFenugreek seedThiobarbituric acidAquatic ScienceProbioticTeleostsGilthead seabream (Sparus aurata L.)law.inventionSuperoxide dismutase03 medical and health sciencesIngredientchemistry.chemical_compoundProbioticRandom AllocationAdjuvants ImmunologicSettore AGR/20 - ZoocolturelawEnvironmental ChemistryAnimalsBacillus licheniformisFood scienceSettore BIO/06 - Anatomia Comparata E Citologiachemistry.chemical_classificationbiologyPlant ExtractsAntioxidant statuProbioticsFatty acid04 agricultural and veterinary sciencesGeneral Medicinebiology.organism_classificationAnimal FeedImmunity InnateSea BreamDietAntioxidant-related gene expression030104 developmental biologyTrigonellachemistryBiochemistryCatalaseDietary Supplements040102 fisheriesbiology.protein0401 agriculture forestry and fisheriesLactobacillus plantarumBacillus subtilisLactobacillus plantarumFishshellfish immunology
researchProduct

Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.

2017

Fully synthetic MUC1 glycopeptide antitumor vaccines have a precisely specified structure and induce a targeted immune response without suppression of the immune response when using an immunogenic carrier protein. However, tumor-associated aberrantly glycosylated MUC1 glycopeptides are endogenous structures, “self-antigens”, that exhibit only low immunogenicity. To overcome this obstacle, a fully synthetic MUC1 glycopeptide antitumor vaccine was combined with poly(inosinic acid:cytidylic acid), poly(I:C), as a structurally defined Toll-like receptor 3 (TLR3)-activating adjuvant. This vaccine preparation elicited extraordinary titers of IgG antibodies which strongly bound human breast cancer…

0301 basic medicinemedicine.medical_treatmentchemical and pharmacologic phenomenaBiochemistryCancer Vaccines03 medical and health sciencesMice0302 clinical medicineImmune systemCancer immunotherapyAdjuvants ImmunologicDrug DiscoverymedicineAnimalsHumansGeneral Pharmacology Toxicology and PharmaceuticsMUC1PharmacologyVaccines SyntheticbiologyChemistryImmunogenicityOrganic ChemistryMucin-1GlycopeptidesDendritic CellsVirologyGlycopeptideToll-Like Receptor 3030104 developmental biologyPoly I-C030220 oncology & carcinogenesisTLR3biology.proteinMolecular MedicineAntibodyAdjuvantChemMedChem
researchProduct

New prospective in treatment of Parkinson's disease: Studies on permeation of ropinirole through buccal mucosa

2012

The aptitude of ropinirole to permeate the buccal tissue was tested using porcine mucosa mounted on Franz-type diffusion cells as ex vivo model. Drug permeation was also evaluated in presence of various penetration enhancers and in iontophoretic conditions. Ropinirole, widely used in treatment of motor fluctuations of Parkinson's disease, passes the buccal mucosa. Flux and permeability coefficient values suggested that the membrane does not appear a limiting step to the drug absorption. Nevertheless, an initial lag time is observed but the input rate can be modulated by permeation enhancement using limonene or by application of electric fields. Absorption improvement was accompanied by the …

Absorption (pharmacology)IndolesTime FactorsSwinePharmaceutical SciencePharmacologyModels BiologicalPermeabilityAntiparkinson AgentsBuccal delivery Ropinirole Parkinson's disease Absorption enhancement Porcine buccal mucosaDrug Delivery SystemsElectricityCyclohexenesmedicineAnimalsAdjuvants PharmaceuticIontophoresisTerpenesChemistryMouth MucosaAdministration BuccalParkinson DiseasePenetration (firestop)Buccal administrationIontophoresisPermeationRopiniroleMembraneSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoFeasibility StudiesLimoneneEx vivomedicine.drugBiomedical engineeringInternational Journal of Pharmaceutics
researchProduct

Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.

2008

BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic …

Adjuvants ImmunologicDiphosphonatesCell Line TumorNeoplasmsT-LymphocytesProtein PrenylationAnimalsHumansReceptors Antigen T-Cell gamma-deltaImmunotherapyHuman gamma delta T cells tumors phosphoantigens bisphosphonates immunotherapyCurrent medicinal chemistry
researchProduct

The transcription factor NFATc2 controls IL-6–dependent T cell activation in experimental colitis

2008

The nuclear factor of activated T cells (NFAT) family of transcription factors controls calcium signaling in T lymphocytes. In this study, we have identified a crucial regulatory role of the transcription factor NFATc2 in T cell–dependent experimental colitis. Similar to ulcerative colitis in humans, the expression of NFATc2 was up-regulated in oxazolone-induced chronic intestinal inflammation. Furthermore, NFATc2 deficiency suppressed colitis induced by oxazolone administration. This finding was associated with enhanced T cell apoptosis in the lamina propria and strikingly reduced production of IL-6, -13, and -17 by mucosal T lymphocytes. Further studies using knockout mice showed that IL-…

Adjuvants Immunologic; Animals; Humans; Interleukin-13; Interleukin-17; Interleukin-6; Lymphocyte Activation; Mice; Mice Inbred BALB C; Mice Knockout; Mice SCID; Models Biological; NFATC Transcription Factors; Oxazolone; T-LymphocytesT cellT-LymphocytesImmunologyMice SCIDBiologyLymphocyte ActivationInflammatory bowel diseaseModels BiologicalArticleOxazoloneTCIRG1chemistry.chemical_compoundMiceAdjuvants ImmunologicmedicineImmunology and AllergyCytotoxic T cellAnimalsHumansColitisMice KnockoutMice Inbred BALB CInterleukin-13NFATC Transcription FactorsInterleukin-6Interleukin-17OxazoloneArticlesmedicine.diseasemedicine.anatomical_structurechemistryImmunologyInterleukin 13Cancer researchInterleukin 17The Journal of Experimental Medicine
researchProduct

B?cells are not required for T?cell priming in low zone tolerance to contact allergens and contact hypersensitivity

2004

Low zone tolerance (LZT) to contact allergens is induced by epicutaneous exposure to haptens in subsensitizing doses resulting in an inhibition of contact hypersensitivity (CHS), which, in contrast, occurs after sensitization with immunogenic doses of allergens. Performing the protocol of tolerance induction resulted in robust LZT to allergens in B cell-deficient mice in vivo, indicating that B cells are not required for the induction and effector phase of LZT. However, CHS reactions in vivo were restricted in B cell-deficient mice as compared to wild-type (WT) mice. In contrast, analysis of hapten-specific T cell activation in vitro revealed a strong proliferative response of T cells deriv…

Adoptive cell transfermedicine.medical_treatmentT cellImmunologyPriming (immunology)Picryl ChlorideCD8-Positive T-LymphocytesBiologyDermatitis ContactLymphocyte ActivationInterferon-gammaMiceAdjuvants ImmunologicImmune TolerancemedicineAnimalsImmunology and AllergySensitizationB cellCell ProliferationMice KnockoutB-Lymphocytesintegumentary systemInterleukinsOxazoloneAllergensAdoptive TransferMice Inbred C57BLTolerance inductionCytokinemedicine.anatomical_structureImmunologyLymph NodesCD8European Journal of Immunology
researchProduct

Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients

2006

A significant percentage of stage II melanoma patients (tumor thickness >1 mm) remain at risk of tumor recurrence after primary tumor excision. In this study, we used tumor antigen-pulsed dendritic cells as an adjuvant for immunization of these “high-risk” melanoma patients after resection of the primary tumor. A total of 13 patients were included and vaccinated 6 times every 14 days with autologous dendritic cells pulsed with a MelanA/MART-1 peptide in combination with a recall antigen. Antigen-specific immune responses were monitored before, during and up to 1 year after the last vaccination. The majority of patients exhibited increased recall antigen-specific CD4+ T cell responses upon v…

AdultCD4-Positive T-LymphocytesCancer ResearchSkin NeoplasmsT cellCD8-Positive T-LymphocytesCancer VaccinesMART-1 AntigenImmune systemAdjuvants ImmunologicAntigens NeoplasmHumansMedicineMelanomaCell Proliferationbusiness.industryMelanomaVaccinationDendritic CellsDendritic cellmedicine.diseasePrimary tumorTumor antigenNeoplasm ProteinsTreatment Outcomemedicine.anatomical_structureddc: 610OncologyImmunizationImmunologybusinessCD8International Journal of Cancer
researchProduct

Rapid High Efficiency Sensitization of CD8+ T Cells to Tumor Antigens by Dendritic Cells Leads to Enhanced Functional Avidity and Direct Tumor Recogn…

2003

Abstract Myeloid-origin dendritic cells (DCs) can develop into IL-12-secreting DC1 or non-IL-12-secreting DC2 depending on signals received during maturation. Through rapid culture techniques that prepared either mature, CD83+ DC1 or DC2 from CD14+ monocytes in only 2 days followed by a single 6–7 day DC-T cell coculture, we sensitized normal donor CD8+ T cells to tumor Ags (HER-2/neu, MART-1, and gp100) such that peptide Ag-specific lymphocytes constituted up to 16% of the total CD8+ population. Both DC1 and DC2 could sensitize CD8+ T cells that recognized peptide-pulsed target cells. However, with DC2, a general decoupling was observed between recognition of peptide-pulsed T2 target cells…

AdultCytotoxicity ImmunologicMaleReceptor ErbB-2CD8 AntigensT cellImmunologyAntigen presentationEpitopes T-LymphocyteStreptamerCD8-Positive T-LymphocytesBiologyLymphocyte ActivationInterleukin 21MART-1 AntigenAdjuvants ImmunologicAntigens NeoplasmT-Lymphocyte SubsetsCell Line TumorCell AdhesionmedicineHumansImmunology and AllergyCytotoxic T cellIL-2 receptorAntigen-presenting cellMelanomaCells CulturedAntigen PresentationMembrane GlycoproteinsCell DifferentiationDendritic CellsInterleukin-12Peptide FragmentsNeoplasm ProteinsCell biologymedicine.anatomical_structureCulture Media ConditionedImmunologyInterleukin 12FemaleImmunizationgp100 Melanoma AntigenThe Journal of Immunology
researchProduct

Effect of cordycepin on interleukin-10 production of human peripheral blood mononuclear cells

2002

Therapeutic options for controlling autoimmune diseases are still very limited. Interleukin-10 has been reported to be a promising approach to therapeutic intervention. In the search for a drug which results in the selective upregulation of interleukin-10, we investigated the immunoregulative effects of cordycepin. We have measured interleukin-10 and interleukin-2 secretion of human peripheral blood mononuclear cells that were incubated with cordycepin and assessed the influence of cordycepin on the expression of interleukin-10 mRNA, the proliferative response and the expression of surface markers on T lymphocytes. In addition, the subsets of interleukin-10-secreting cells, the influence of…

AdultInterleukin 2T-Lymphocytesmedicine.medical_treatmentPharmacologyBiologyLymphocyte ActivationPeripheral blood mononuclear cellchemistry.chemical_compoundAdjuvants ImmunologicAntigens CDmedicineHumansRNA MessengerIL-2 receptorCells CulturedPharmacologyDeoxyadenosinesDose-Response Relationship DrugCordycepinMonocyteInterleukinFlow CytometryInterleukin-10Up-RegulationInterleukin 10medicine.anatomical_structureCytokinechemistryImmunologyLeukocytes MononuclearInterleukin-2Cell Divisionmedicine.drugEuropean Journal of Pharmacology
researchProduct

Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune res…

2021

Significance Vaccines profit from the addition of adjuvants to better and more specifically initiate, amplify, and shape immune responses. Although the number of adjuvant candidates has steadily increased, peaking in the current SARS-CoV-2 pandemic, little is known about their inherent mode of action. Using human blood immune cells, we established a multilayer method to systematically assess the adjuvants’ effects on innate and adaptive immune cells. By employing a multiplex analysis with cells from 30 different donors, we determined important patterns of adjuvant function. Moreover, we demonstrate correlates of an antiviral immune response using a Toll-like receptor 7/8 ligand adjuvant and…

AdultMaleAdolescentT-LymphocytesMonophosphoryl Lipid ALipid Achemistry.chemical_compoundImmunology and InflammationImmune systemAdjuvants ImmunologicInterferonTLRmedicineHumansprimary human cellsAgedImmunity CellularToll-like receptorMultidisciplinarySARS-CoV-2ChemistryToll-Like ReceptorsImidazolesCOVID-19Dendritic CellsTLR7biochemical phenomena metabolism and nutritionBiological SciencesMiddle AgedCOVID-19 ; TLR ; primary human cells ; adjuvants ; mRNA vaccines420Cell biologymRNA vaccinesLipid AadjuvantsTLR4[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleResiquimodmedicine.drugProceedings of the National Academy of Sciences
researchProduct